Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: A substudy of Dutch patients in the TEAM trial

Additional Metadata
Keywords	Adverse events, Aromatase inhibitors, Breast cancer, Cyp19, Exemestane, Pharmacogenetics, Pharmacotherapy
Persistent URL	doi.org/10.1007/s10549-014-2873-2, hdl.handle.net/1765/89073
Journal	Breast Cancer Research and Treatment
Rights	no subscription
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Fontein, D.B.Y, Houtsma, D, Nortier, J.W.R, Baak-Pablo, R.F, Kranenbarg, E.M.-K, van der Straaten, T.J, … Guchelaar, H.J. (2014). Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: A substudy of Dutch patients in the TEAM trial. Breast Cancer Research and Treatment, 144(3), 599–606. doi:10.1007/s10549-014-2873-2

Publication